Insider Buying: Neonc Technologies (NASDAQ:NTHI) CEO Acquires 20,000 Shares of Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour acquired 20,000 shares of the company’s stock in a transaction on Wednesday, November 11th. The shares were bought at an average price of $4.25 per share, for a total transaction of $85,000.00. Following the completion of the purchase, the chief executive officer owned 3,333,000 shares in the company, valued at approximately $14,165,250. This represents a 0.60% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Neonc Technologies Trading Up 3.4%

Shares of NASDAQ:NTHI opened at $4.52 on Thursday. Neonc Technologies Holdings, Inc. has a twelve month low of $2.50 and a twelve month high of $12.00. The company has a 50-day moving average price of $3.30 and a two-hundred day moving average price of $5.31.

Neonc Technologies (NASDAQ:NTHI) last announced its earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.03).

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of NTHI. Bank of America Corp DE lifted its holdings in shares of Neonc Technologies by 5.0% during the first quarter. Bank of America Corp DE now owns 235,396 shares of the company’s stock worth $1,650,000 after purchasing an additional 11,108 shares during the period. Westmount Partners LLC raised its holdings in shares of Neonc Technologies by 355.2% during the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after purchasing an additional 153,858 shares during the last quarter. BlackRock Inc. acquired a new position in Neonc Technologies during the second quarter valued at $815,000. Finally, Global Retirement Partners LLC acquired a new position in Neonc Technologies during the second quarter valued at $126,000.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Wall Street Zen raised shares of Neonc Technologies from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Weiss Ratings downgraded Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, October 21st. BTIG Research restated a “buy” rating and set a $15.00 target price on shares of Neonc Technologies in a research report on Tuesday, September 8th. Roth Capital began coverage on shares of Neonc Technologies in a research note on Thursday, September 24th. They issued a “buy” rating on the stock. Finally, Zacks Research upgraded shares of Neonc Technologies from a “strong sell” rating to a “hold” rating in a report on Thursday, November 5th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Neonc Technologies Company Profile

NeOnc Technologies Holdings, Inc. is a biotechnology company developing treatments for brain tumors and other central nervous system cancers. Its research focuses on approaches intended to deliver therapies to the brain, where the blood-brain barrier can limit the effectiveness of conventional treatments. The company’s pipeline includes NEO100, a formulation of perillyl alcohol designed for intranasal delivery, and NEO212, a compound combining perillyl alcohol with temozolomide. These candidates are being developed for potential use in brain cancer treatment.